Carfilzomib

證據等級: L5

預測適應症: 5 個

Carfilzomib: From Multiple Myeloma to Melanoma

One-Sentence Summary

Carfilzomib is an irreversible 26S proteasome inhibitor used internationally to treat relapsed/refractory multiple myeloma (not currently marketed in Norway per this Evidence Pack). The TxGNN model predicts activity in Melanoma, supported by 0 clinical trials and 5 preclinical/in-silico publications — no clinical evidence exists yet. TxGNN also scored four narrower melanoma-subtype terms (CMM7, pediatric leptomeningeal melanoma, epithelioid uveal melanoma, vulvar melanoma) even higher, but these carry zero supporting evidence and are flagged "Hold" — they are noted for transparency but not used as the headline indication.

Quick Overview

Item	Content
Original Indication	Multiple Myeloma (relapsed/refractory) — based on internationally known drug class; not documented in Norway regulatory data (drug not marketed)
Predicted New Indication	Melanoma
TxGNN Prediction Score	99.03% (rank 9297)
Evidence Level	L4 (preclinical/mechanistic studies only)
Norway Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Other TxGNN-ranked melanoma-related terms (no supporting evidence, all Hold/L5):

Disease	TxGNN Score	Note
CMM7	99.37%	Disease definition unclear (possible melanoma molecular subtype); no evidence
Pediatric leptomeningeal melanoma	99.30%	Ultra-rare pediatric CNS subtype; blood-brain barrier penetration unknown; no evidence
Epithelioid cell uveal melanoma	99.23%	Distinct GNAQ/GNA11-driven biology from cutaneous melanoma; no evidence
Vulvar melanoma	99.19%	Rare mucosal subtype with distinct molecular profile; no evidence

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack (DG002). Based on known pharmacology, carfilzomib is an irreversible 26S proteasome inhibitor: it blocks proteasomal degradation of ubiquitinated proteins, causing intracellular accumulation of misfolded proteins, inhibition of the NF-κB pathway, ER stress, and downstream apoptosis. It is established (internationally) for multiple myeloma, a hematologic malignancy that is highly dependent on proteasome function for survival.

Melanoma is biologically distinct from multiple myeloma (solid tumor vs. hematologic), so the mechanistic bridge relies on a shared vulnerability to proteasome stress rather than tissue-specific overlap. A single in vitro study (B16-F1 mouse melanoma cells) showed apoptosis induction with carfilzomib combined with bortezomib, evidenced by caspase 3/8/9/12 activation. The remaining literature is either indirect (kinase-target docking screens, NF-κB/heparanase mechanism studies in myeloma models, PROTAC degrader studies) rather than melanoma-specific efficacy data.

Overall, the biological rationale is plausible but thin: it rests on one preclinical cell-line study, with no in vivo, clinical, or human translational data. The four higher-scoring subtype predictions (CMM7, pediatric leptomeningeal, uveal, vulvar melanoma) currently have no literature or trial support at all and should be treated as algorithmic signals only.

Clinical Trial Evidence

Currently no related clinical trials registered (across all five predicted melanoma-related indications).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33671902	2021	Preclinical (in vitro)	Biology	Carfilzomib + bortezomib induced apoptosis in B16-F1 melanoma cells via caspase 3/8/9/12 activation
36134605	2023	In silico (docking/simulation)	J Biomol Struct Dyn	Molecular docking/dynamics screen across 10 cancer types (incl. melanoma) against 18 kinase targets for drug repurposing
27016342	2016	Preclinical (mechanism)	Matrix Biology	Bortezomib/carfilzomib activate NF-κB and upregulate heparanase, associated with aggressive tumor phenotype (myeloma model)
31540997	2019	Preclinical (gene regulation)	Mol Cancer Res	AIRAP/ZFAND2A gene regulates melanoma cell survival via E3-ligase cIAP2; proteasome-stress pathway relevance
29581547	2018	Preclinical (PROTAC/BET degrader)	Leukemia	BET-degrading PROTACs active in myeloma preclinical models; proteasome-dependent mechanism context

No RCTs, reviews, or case reports are available; all evidence is preclinical or in silico.

Norway Market Information

Carfilzomib is not marketed in Norway (0 authorizations on file). No license or approved-indication text is available in this Evidence Pack.

Cytotoxicity

Carfilzomib is an antineoplastic agent (proteasome inhibitor class), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (proteasome inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Standard antineoplastic drug handling precautions apply per institutional protocol; formal TFDA/label guidance not yet available (see DG001)

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or DDI data are currently available in this Evidence Pack (DG001, Blocking severity).

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for melanoma is limited to a single in vitro cell-line study with no in vivo, clinical, or human data (L4/S1), and the four higher-scoring melanoma-subtype signals have no supporting evidence at all. Combined with the absence of Norway market authorization and a Blocking data gap on TFDA label safety information, the candidate cannot proceed past initial screening.

To proceed, the following is needed:

TFDA label / package insert data (warnings, contraindications) — required to clear the Blocking gap before any S1 safety review (DG001)
Confirmed original MOA and indication documentation from DrugBank or equivalent source (DG002)
In vivo preclinical or early clinical evidence specifically supporting melanoma before advancing beyond S1
Clarification of disease-term definitions for CMM7 and the other subtype predictions, as these appear to be data-quality artifacts rather than actionable signals
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.